Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)

Clinical trial NCT03094832 · TERMINATED

Trial details

NCT number: NCT03094832
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

Start date: 2017-05-16
Primary completion: 2022-04-11
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.